Kewaunee Scientific Corp.

As of September 11, 2025, Kewaunee Scientific Corp. shows a mildly bearish trend despite a recent 5.85% weekly outperformance compared to the S&P 500, with year-to-date returns at -26.30% versus the S&P's 12.22%.

As of June 30, 2025, Kewaunee Scientific Corp. is considered undervalued with a P/E ratio of 6 and strong long-term performance, despite a year-to-date return of -26.30%, contrasting with the S&P 500's 12.22% return.

As of May 27, 2025, the technical trend is mildly bearish, indicated by a bearish MACD and moving averages, despite a mildly bullish KST signal, leading to a cautious overall sentiment.

As of May 8, 2025, Kewaunee Scientific Corp. is considered attractively undervalued with a P/E ratio of 6, strong ROE and ROCE metrics, and a PEG ratio of 0.06, despite recent underperformance against the S&P 500, indicating potential for recovery and value realization.

As of March 2022, the management team of Kewaunee Scientific Corp. includes Mr. David Rhind (Independent Chairman), Mr. Thomas Hull (President and CEO), and four Independent Directors: Mr. Keith Gehl, Ms. Margaret Pyle, Mr. John Russell, and Mr. Donald Shaw. They oversee the company's operations and strategic direction.

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory and healthcare furniture products, operating in the Pharmaceuticals & Biotechnology industry. As of January 2025, it reported net sales of $67 million and a market cap of $105.10 million.

As of Jun 18, Kewaunee Scientific Corp. has a market capitalization of 105.10 million and reported net sales of 220.02 million and a net profit of 17.82 million over the latest four quarters.